Yinci Zhang

630 total citations
23 papers, 458 citations indexed

About

Yinci Zhang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yinci Zhang has authored 23 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yinci Zhang's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer Mechanisms and Therapy (4 papers). Yinci Zhang is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer Mechanisms and Therapy (4 papers). Yinci Zhang collaborates with scholars based in China. Yinci Zhang's co-authors include Amin Li, Shuping Zhou, Xinkuang Liu, Jiaojiao Liang, Weiya Cao, Jiafeng Gao, Xueke Liu, Ruyue Xu, Yongfang Ma and Yong Liang and has published in prestigious journals such as PLoS ONE, Journal of Cellular Physiology and Materials Science and Engineering C.

In The Last Decade

Yinci Zhang

23 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yinci Zhang China 15 252 98 92 84 72 23 458
Amin Li China 15 233 0.9× 80 0.8× 101 1.1× 88 1.0× 79 1.1× 25 428
Mingmei Liao China 13 274 1.1× 117 1.2× 44 0.5× 91 1.1× 41 0.6× 15 566
Allen Zhang United States 10 397 1.6× 141 1.4× 40 0.4× 133 1.6× 34 0.5× 16 565
Jiafeng Gao China 15 250 1.0× 101 1.0× 39 0.4× 79 0.9× 22 0.3× 22 472
Xuefeng Liu China 11 265 1.1× 195 2.0× 30 0.3× 115 1.4× 35 0.5× 21 528
Stefania Porto Italy 12 254 1.0× 161 1.6× 54 0.6× 121 1.4× 17 0.2× 13 593
Jinggang Mo China 13 246 1.0× 178 1.8× 33 0.4× 87 1.0× 67 0.9× 36 516
Kelin Zhang China 14 207 0.8× 110 1.1× 21 0.2× 67 0.8× 51 0.7× 22 457
Dar-Shih Hsieh Taiwan 13 187 0.7× 71 0.7× 93 1.0× 100 1.2× 18 0.3× 23 501
Xiong‐Zhi Wu China 12 190 0.8× 134 1.4× 41 0.4× 109 1.3× 122 1.7× 15 452

Countries citing papers authored by Yinci Zhang

Since Specialization
Citations

This map shows the geographic impact of Yinci Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yinci Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yinci Zhang more than expected).

Fields of papers citing papers by Yinci Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yinci Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yinci Zhang. The network helps show where Yinci Zhang may publish in the future.

Co-authorship network of co-authors of Yinci Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Yinci Zhang. A scholar is included among the top collaborators of Yinci Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yinci Zhang. Yinci Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Yinci, et al.. (2025). Occupational nanoparticles: major sources, physicochemical properties, multi-organ toxic effects, and associated mechanisms. Toxicology Mechanisms and Methods. 35(8). 847–864. 2 indexed citations
2.
Zhang, Yinci, et al.. (2024). Redefinition of Synovial Fibroblasts in Rheumatoid Arthritis. Aging and Disease. 16(4). 2054–2054. 4 indexed citations
3.
Zhang, Yinci, et al.. (2023). Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma. The Clinical Respiratory Journal. 17(12). 1301–1315. 3 indexed citations
4.
Gao, Yuchen, Jiaxin Tang, Caishi Zhang, et al.. (2023). OTUD4 regulates metastasis and chemoresistance in melanoma by stabilizing Snail1. Journal of Cellular Physiology. 238(11). 2546–2555. 7 indexed citations
5.
6.
Zhang, Yinci, et al.. (2022). A pan-cancer analysis on the carcinogenic effect of human adenomatous polyposis coli. PLoS ONE. 17(3). e0265655–e0265655. 13 indexed citations
7.
8.
Zhang, Yinci, et al.. (2022). Differences in the characteristics and pulmonary toxicity of nano- and micron-sized respirable coal dust. Respiratory Research. 23(1). 197–197. 12 indexed citations
9.
Zhang, Yinci, et al.. (2022). ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. Journal of Cellular and Molecular Medicine. 26(10). 2777–2792. 24 indexed citations
10.
Cao, Weiya, Yinci Zhang, Amin Li, et al.. (2021). Curcumin reverses hepatic epithelial mesenchymal transition induced by trichloroethylene by inhibiting IL-6R/STAT3. Toxicology Mechanisms and Methods. 31(8). 589–599. 19 indexed citations
11.
Liu, Changwei, et al.. (2021). PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair. PLoS ONE. 16(10). e0258817–e0258817. 19 indexed citations
12.
Xu, Ruyue, Yinci Zhang, Amin Li, et al.. (2021). LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway. Molecular Medicine Reports. 24(1). 22 indexed citations
13.
Ma, Yongfang, Ruyue Xu, Xueke Liu, et al.. (2021). LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. International Journal of Medical Sciences. 18(6). 1456–1464. 28 indexed citations
14.
Shen, Jing, Yongfang Ma, Ruyue Xu, et al.. (2020). hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway. Nanoscale Research Letters. 15(1). 220–220. 17 indexed citations
15.
Li, Amin, Weiya Cao, Xueke Liu, et al.. (2020). Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. Journal of Cancer Research and Clinical Oncology. 146(7). 1737–1749. 14 indexed citations
16.
Li, Amin, Weiya Cao, Xueke Liu, et al.. (2020). Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells. Translational Cancer Research. 9(9). 5473–5483. 1 indexed citations
17.
Zhang, Yinci, Chunmei Xie, Amin Li, et al.. (2019). PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway.. PubMed. 11(8). 5134–5149. 36 indexed citations
18.
Li, Amin, Rongbo Zhang, Yinci Zhang, et al.. (2019). BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.. PubMed. 11(9). 5573–5585. 29 indexed citations
19.
Li, Amin, Yinci Zhang, Xueke Liu, et al.. (2018). Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma. Materials Science and Engineering C. 91. 395–403. 45 indexed citations
20.
Tang, Xiaolong, Amin Li, Yinci Zhang, et al.. (2018). Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Delivery. 25(1). 1484–1494. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amin Li Breakdown of academic impact, for papers by Mingmei Liao Breakdown of academic impact, for papers by Allen Zhang Breakdown of academic impact, for papers by Jiafeng Gao Breakdown of academic impact, for papers by Xuefeng Liu Breakdown of academic impact, for papers by Stefania Porto Breakdown of academic impact, for papers by Jinggang Mo Breakdown of academic impact, for papers by Kelin Zhang Breakdown of academic impact, for papers by Dar-Shih Hsieh Breakdown of academic impact, for papers by Xiong‐Zhi Wu
Rankless by CCL
2026